Pfizer Chair Discusses Regulation of Drug Ads, Congressional Efforts to Ensure Safety

Main Category: Pharma Industry / Biotech Industry
Article Date: 19 May 2005 - 11:00 PDT

email to a friend   printer friendly   opinions  

Pfizer Chair Hank McKinnell on Tuesday said the company supports a proposal in Congress that would require pharmaceutical companies to submit all advertising to... FDA for advance review, the Boston Globe reports (Henderson, Boston Globe, 5/18). Introduced in April by Senate Finance Committee Chair Chuck Grassley (R-Iowa) and Sen. Christopher Dodd (D-Conn.), the bill would require pharmaceutical companies to seek approval from a new Center for Postmarket Drug Evaluation and Research for advertisements for new prescription drugs, high-risk medications and treatments not tested in post-market clinical trials (Kaiser Daily Health Policy Report, 4/28). McKinnell said that the company works to comply with FDA advertising rules, but "[s]ometimes, we get it wrong. We certainly can submit everything before we run it. And if they don't like it, they ought to tell us before we run it, rather than after." He noted that advertisements do a "great job" of promoting brands but fail to adequately convey medication risks. However, McKinnell was "less receptive" to other provisions in drug-safety legislation in Congress, including the creation of an independent drug-safety center at FDA, the Globe reports. McKinnell said such a center would create "a giant game of gotcha" between FDA departments. Meanwhile, he also said he opposes a bill that would require the publication of early trials, noting that doing so could raise false hopes for patients who view unconfirmed studies. He added that a promise from FDA to provide information to the public about drug risks as they become available could scare people unnecessarily. According to the Globe, Pfizer has stopped most advertising while company officials develop campaigns that better inform patients about drug risks, their diseases and the need to talk to physicians about treatment (Boston Globe, 5/18).

Pfizer

"Reprinted with permission from kaisernetwork.org kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

• Additional
• References
• Citations